Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

被引:7
|
作者
Shi, Zhong-Xing [1 ]
Li, Chang -Fu [2 ]
Zhao, Li-Feng [3 ]
Sun, Zhong-Qi [4 ]
Cui, Li -Ming [1 ]
Xin, Yan-Jie [4 ]
Wang, Dong-Qing [1 ]
Kang, Tan-Rong [1 ]
Jiang, Hui-Jie [4 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China
[2] Daqing Longnan Hosp, Dept Digest Med, Daqing 163453, Peoples R China
[3] Daqing Longnan Hosp, Dept Radiol, Daqing 163453, Peoples R China
[4] Harbin Med Univ, Affiliated Hosp 2, Dept Radiol, Harbin 150086, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Treatment response; Prediction; PROGNOSIS;
D O I
10.1016/j.hbpd.2023.06.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to clinical practice guidelines, transarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate -stage hepatocellular carcinoma (HCC). Early prediction of treatment response can help patients choose a reasonable treatment plan. This study aimed to investigate the value of the radiomic-clinical model in predicting the efficacy of the first TACE treatment for HCC to prolong patient survival. Methods: A total of 164 patients with HCC who underwent the first TACE from January 2017 to September 2021 were analyzed. The tumor response was assessed by modified response evaluation criteria in solid tumors (mRECIST), and the response of the first TACE to each session and its correlation with overall survival were evaluated. The radiomic signatures associated with the treatment response were identified by the least absolute shrinkage and selection operator (LASSO), and four machine learning models were built with different types of regions of interest (ROIs) (tumor and corresponding tissues) and the model with the best performance was selected. The predictive performance was assessed with receiver operating characteristic (ROC) curves and calibration curves. Results: Of all the models, the random forest (RF) model with peritumor ( + 10 mm) radiomic signatures had the best performance [area under ROC curve (AUC) = 0.964 in the training cohort, AUC = 0.949 in the validation cohort]. The RF model was used to calculate the radiomic score (Rad-score), and the optimal cutoff value (0.34) was calculated according to the Youden's index. Patients were then divided into a high -risk group (Rad-score > 0.34) and a low -risk group (Rad-score <= 0.34), and a nomogram model was successfully established to predict treatment response. The predicted treatment response also allowed for significant discrimination of Kaplan -Meier curves. Multivariate Cox regression identified six independent prognostic factors for overall survival, including male [hazard ratio (HR) = 0.500, 95% confidence interval (CI): 0.260-0.962, P = 0.038], alpha-fetoprotein (HR = 1.003, 95% CI: 1.002-1.004, P < 0.001), alanine aminotransferase (HR = 1.003, 95% CI: 1.0 01-1.0 05, P = 0.025), performance status (HR = 2.400, 95% CI: 1.20 0-4.80 0, P = 0.013), the number of TACE sessions (HR = 0.870, 95% CI: 0.780-0.970, P = 0.012) and Rad-score (HR = 3.480, 95% CI: 1.416-8.552, P = 0.007). Conclusions: The radiomic signatures and clinical factors can be well -used to predict the response of HCC patients to the first TACE and may help identify the patients most likely to benefit from TACE. (c) 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 50 条
  • [31] Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study
    Wang, Dan-Dan
    Zhang, Jin-Feng
    Zhang, Lin-Han
    Niu, Meng
    Jiang, Hui-Jie
    Jia, Fu-Cang
    Feng, Shi-Ting
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (06) : 594 - 604
  • [32] The value of computed tomography perfusion for assessing the response of hepatocellular carcinoma to transarterial chemoembolization
    Huynh, Bui Quang
    Hung, Nguyen Duy
    Dung, Le Thanh
    Thu, Nguyen-Thi
    Anh, Nguyen-Thi Hai
    Duy, Ngo Quang
    Duc, Nguyen Minh
    ITALIAN JOURNAL OF MEDICINE, 2024, 18 (03)
  • [33] Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE)
    Fernandez-Palanca, Paula
    Mauriz, Jose L.
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (02)
  • [34] Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE)
    Lencioni, R.
    Zou, J.
    Leberre, M.
    Meinhardt, G.
    Voliotis, D.
    Bruix, J.
    Llovet, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization
    Liu, Guanghua
    Xia, Fang
    Fan, Guoping
    Yu, Juming
    Bao, Lei
    Zhang, Caiyuan
    Chi, Runmin
    Zhang, Tingting
    Wang, Lijun
    Shen, Feng
    Wang, Dengbin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 169
  • [36] Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma
    Xiang, Yan-Jun
    Wang, Kang
    Yu, Hong-Ming
    Li, Xiao-Wei
    Cheng, Yu-Qiang
    Wang, Wei-Jun
    Feng, Jin-Kai
    Bo, Meng-Han
    Qin, Ying-Yi
    Zheng, Yi-Tao
    Shan, Yun-Feng
    Zhou, Li-Ping
    Zhai, Jian
    Cheng, Shu-Qun
    HEPATOLOGY RESEARCH, 2022, 52 (08) : 721 - 729
  • [37] Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function
    Saito, Natsuhiko
    Tanaka, Toshihiro
    Nishiohuku, Hideyuki
    Sato, Takeshi
    Masada, Tetsuya
    Matsumoto, Takeshi
    Anai, Hiroshi
    Sakaguchi, Hiroshi
    Sueyoshi, Satoru
    Marugami, Nagaaki
    Kichikawa, Kimihiko
    HEPATOLOGY RESEARCH, 2020, 50 (10) : 1176 - 1185
  • [38] THE COMPARISON BETWEEN OVERALL SURVIVAL OF TRANSARTERIAL CHEMOEMBOLIZATION AND BEST SUPPORTIVE CARE IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
    Akarapatima, Keerati
    Chang, Arunchai
    Prateepchaiboon, Tanaporn
    Pungpipattrakul, Nuttanit
    Songjamrat, Apiradee
    Pakdeejit, Songklod
    Rattanasupar, Attapon
    GUT, 2021, 70 : A73 - A74
  • [39] Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection
    Chi, Chen-Ta
    Lee, I-Cheng
    Lee, Rheun-Chuan
    Hung, Ya-Wen
    Su, Chien-Wei
    Hou, Ming-Chih
    Chao, Yee
    Huang, Yi-Hsiang
    CANCERS, 2021, 13 (17)
  • [40] Role of preoperative transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (Hong Kong liver cancer stage IIB)
    Nandy, Kunal
    Varty, Gurudutt P.
    Patkar, Shraddha
    Shah, Tanvi
    Gundavda, Kaival
    Gala, Kunal
    Shetty, Nitin
    Kulkarni, Suyash
    Goel, Mahesh
    WORLD JOURNAL OF SURGERY, 2025, 49 (02) : 483 - 493